Practice

Julie Reed: The Status Quo for Biosimilars Needs to Change to Maintain the Industry

May 11th 2023

By Skylar Jeremias

The 2023 Asembia Specialty Pharmacy Summit featured Juliana (Julie) Reed, executive director of the Biosimilars Forum, who spoke on the challenges still facing the biosimilars industry and how they may impact the success of adalimumab biosimilars in the United States.

Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology

May 9th 2023

By Skylar Jeremias

Article

Colby Evans, MD, a dermatologist and co-author of an American Journal of Managed Care® supplement “Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update" shares the managed care perspective on using biosimilars to treat inflammatory conditions.

RWE: Rituximab Biosimilar GP2013 Effective in Patients With RA After Switching From Originator

May 8th 2023

By Deana Ferreri, PhD

Article

In a study including 2 years of real-world evidence (RWE), patients with rheumatoid arthritis (RA) who were switched from originator rituximab (Rituxan) to GP2013, a rituximab biosimilar, experienced positive results and maintained clinical outcomes.

Long-term Phase 3 Results Show Similar Efficacy, Cardiac Safety of SB3 vs Herceptin

May 6th 2023

By Deana Ferreri, PhD

Article

The authors of what they say is the largest and longest follow-up study comparing the trastuzumab biosimilar SB3 to the reference product (Herceptin) in HER2-positive breast cancer found “no clinically meaningful difference” between the biosimilar and the reference product.

Asembia: Payers More Likely to Prefer Multiple Biosimilars for the Same Reference Product

May 4th 2023

By Skylar Jeremias

Article

In a panel at the 2023 Asembia Specialty Pharmacy Summit, speakers presented on the payer perspective regarding biosimilars, including that they feel comfortable preferring multiple biosimilars for the same reference product and are looking for interchangeability designations.

Despite Concerns Over Extrapolation, Bevacizumab Biosimilars Are Widely Used in mCRC

May 3rd 2023

By Deana Ferreri, PhD

Article

A review article investigating the use of bevacizumab biosimilars found that despite lingering concerns about their usage for extrapolated indications, bevacizumab biosimilars are regularly used in metastatic colorectal cancer (mCRC) even though clinical tests only evaluate them in patients with lung cancer.

Study on Nonmedical Switching for Adalimumab Biosimilars Warns About Nocebo Effect

April 27th 2023

By Skylar Jeremias

Article

Nonmedical switches from Humira (reference adalimumab) to a biosimilar or an adalimumab biosimilar to another biosimilar resulted in nocebo effect responses, suggesting that more communication between providers and patients is needed, according to a real-world analysis.

Multiple Infliximab Biosimilar Switches Appear Safe, Effective for Patients With IBD

April 20th 2023

By Justina Petrullo

Article

A retrospective study in Scotland found that multiple successive changes from originator infliximab to biosimilars seem to be safe and effective in patients with inflammatory bowel disease (IBD), irrespective of the number of switches.

Similar Overall Survival, Shorter Progression-Free Survival With Rituximab Biosimilar in Patients With DLBCL vs Originator

April 18th 2023

By Deana Ferreri, PhD

Article

Authors of a single-center, real-world study in Turkey found that patients with diffuse large B-cell lymphoma (DLBCL) who received a rituximab biosimilar had similar overall survival to patients who received the originator. However, progression-free survival was longer in the originator group.

Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars

April 16th 2023

By Skylar Jeremias

Podcast

What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.